PIKTOR
Endometrial cancer, Breast cancer
Phase 1b (assumed)Active
Key Facts
Indication
Endometrial cancer, Breast cancer
Phase
Phase 1b (assumed)
Status
Active
Company
About Sensei Biotherapeutics
Sensei Biotherapeutics is a Boston-based, clinical-stage biotech focused on next-generation cancer therapeutics. Following a transformative 2024 acquisition, the company's strategy now centers on PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor combined with dietary intervention, representing a novel metabolic modulation approach. The company is also advancing solnerstotug, a VISTA-targeting immunotherapy, through Phase 1/2 trials. With a compact pipeline and a distressed public market valuation, Sensei represents a high-risk, high-potential turnaround story in the competitive oncology landscape.
View full company profile